Quarterly report pursuant to Section 13 or 15(d)

Earning (Loss) Per Share

v3.23.2
Earning (Loss) Per Share
6 Months Ended
Jun. 30, 2023
Earnings Per Share [Abstract]  
Earning (Loss) Per Share

Note 3 – Earning (Loss) Per Share

 

The earnings (loss) per share accounting guidance is discussed in Note 1. The following table sets forth the computation of the Company’s basic and diluted net earnings (loss) per share available to common stockholders (unaudited) for the three and six months ended June 30, 2023 and 2022:

    2023     2022     2023     2022  
    Three Months Ended June 30,     Six Months Ended June 30,  
    2023     2022     2023     2022  
Numerator                        
Net income (loss) from continuing operations   $ 1,285,930     $ (499,841 )   $ 2,091,490     $ (2,765,973 )
Deemed dividends     -       (194,951,624 )     -       (330,876,369 )
Net income (loss) available to common stockholders, continuing operations     1,285,930       (195,451,465 )     2,091,490       (333,642,342 )
Net loss from discontinued operations     (8,097 )     (3,945 )     (8,097 )     (5,379 )
Net income (loss) available to common stockholders   $ 1,277,833     $ (195,455,410 )   $ 2,083,393     $ (333,647,721 )
                                 
Denominator                                
Weighted average number of shares of common stock outstanding during the period - basic     29,934,322,257       1,702,149,425       29,845,095,738       858,169,865  
  Warrants     -       -       6,335,103,465       -  
  Preferred stock     452,145,411,111       -       452,234,637,630       -  
Weighted average number of shares of common stock outstanding during the period - diluted     482,079,733,368       1,702,149,425       488,414,836,833       858,169,865  
                                 
Net earnings (loss) available to common stockholders per share - basic:                                
Continuing operations   $ 0.00     $ (0.11 )   $ 0.00     $ (0.39 )
Discontinued operations     (0.00 )     (0.00 )     (0.00 )     (0.00 )
Total basic   $ 0.00     $ (0.11 )   $ 0.00     $ (0.39 )
Net earnings (loss) available to common stockholders per share - diluted:                                
Continuing operations   $ 0.00     $ (0.11 )   $ 0.00     $ (0.39 )
Discontinued operations     (0.00 )     (0.00 )     (0.00 )     (0.00 )
Total diluted   $ 0.00     $ (0.11 )   $ 0.00     $ (0.39 )

 

 

Diluted earnings (loss) per share excludes all dilutive potential shares if their effect is anti-dilutive.

 

For the three months ended June 30, 2023 and 2022, the following potential common stock equivalents were excluded from the calculation of diluted earnings (loss) per share as their effect was anti-dilutive:

 

    2023     2022  
    Three Months Ended June 30,  
    2023     2022  
Common stock warrants     511,333,351,089       511,333,351,097  
Convertible preferred stock     -       477,576,633,334  
Convertible debentures     28,777,833,333       28,777,833,333  
Stock options     26       26  
Anti-dilutive shares     540,111,184,448       1,017,687,817,790  

 

For the six months ended June 30, 2023 and 2022, the following potential common stock equivalents were excluded from the calculation of diluted earnings (loss) per share as their effect was anti-dilutive:

 

    2023     2022  
    Six Months Ended June 30,  
    2023     2022  
Common stock warrants     504,998,247,624       511,333,351,097  
Convertible preferred stock     -       477,576,633,334  
Convertible debentures     28,777,833,333       28,777,833,333  
Stock options     26       26  
Anti-dilutive shares     533,776,080,983       1,017,687,817,790  

 

The terms of certain of the warrants, convertible preferred stock and convertible debentures issued by the Company provide for reductions in the per share exercise prices of the warrants and the per share conversion prices of the debentures and preferred stock (if applicable and subject to floors in certain cases) in the event that the Company issues common stock or common stock equivalents (as that term is defined in the agreements) at an effective exercise/conversion price that is less than the then exercise/conversion prices of the outstanding warrants, preferred stock or debentures, as the case may be. In addition, many of these securities contain exercise or conversion prices that vary based upon the price of the Company’s common stock on the date of exercise/conversion (see Notes 6, 9 and 10). These provisions have resulted in significant dilution of the Company’s common stock.

 

As a result of the Voting Agreement and Irrevocable Proxy (the “Voting Agreement”) discussed in Note 10 and the November 5, 2021 Amendment to the Company’s Certificate of Incorporation, as amended, to provide that the number of authorized shares of the Company’s common stock or preferred stock may be increased or decreased (but not below the number of shares then outstanding) by the affirmative vote of the holders of a majority in voting power of the stock of the Company, which is more fully discussed in Note 1, as of the date of filing this report, the Company believes that it has the ability to ensure that it has and or can obtain sufficient authorized shares of its common stock to cover all outstanding rights to acquire potentially dilutive common shares.

 

As a result of these down round provisions, the potential common stock and common stock equivalents totaled 1.0 trillion at August 8, 2023. See Note 10 for a discussion of the number of shares of the Company’s authorized common and preferred stock.